

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Canceled):
2. (Currently amended): A method for the diagnosis of first presentation or recurrence of bladder cancer in a patient, the method consisting of:
  - (a) obtaining a urine sample from the patient;
  - (b) detecting the presence of a 37 kDa fragment of EGFR in the urine sample using an antibody Ab4 that specifically binds the 37 kDa EGFR fragment; wherein the presence of the 37 kDa fragment of EGFR in the sample indicates that the patient has bladder cancer.
- 3-9. (Canceled):
10. (Currently amended): A method for the diagnosis of bladder cancer and/or a urinary infection in a patient, the method consisting of:
  - (a) obtaining a urine sample from the patient;
  - (b) detecting the presence of a 37 kDa fragment of EGFR in the urine sample using an antibody Ab4 that specifically binds the 37 kDa EGFR fragment; wherein the presence of the 37 kDa fragment of EGFR in the sample indicates that the patient has bladder cancer and/or a urinary infection.
11. (Previously presented): A method as claimed in claim 10 in the form of a dip-stick test.
- 12-13. (Canceled):

14. (Previously presented): A method as claimed in claim 2 in the form of a dip-stick test.
15. (Currently amended): A method for assessing genitourinary health of a patient, the method comprising:
  - (a) obtaining a urine sample from the patient; and
  - (b) detecting the presence of a 37 kDa fragment of EGFR in the urine sample using an antibody Ab4 that specifically binds the 37 kDa EGFR fragment; wherein the absence of the 37 kDa fragment of EGFR in the sample indicates that the patient is in good genitourinary health, and wherein the presence of the 37 kDa fragment of EGFR in the sample indicates the possibility that the patient has one or more of the following:
    - (i) a urinary infection;
    - (ii) prostate cancer; and
    - (iii) a bladder tumor.
16. (Previously presented) The method of claim 15, where if the 37 kDa fragment of EGFR is detected in the sample, the method further comprises one or more of the following:
  - (m) treatment of a urinary infection;
  - (n) testing for prostate cancer; and
  - (o) testing for a bladder tumor.
17. (Canceled):
18. (Previously presented): The method of claim 15, wherein the presence of the 37 kDa fragment of EGFR is detected by use of a dip-stick test.
19. (Canceled):